胃泌素抑制肽(GIP)牛血清白蛋白偶聯(lián)物
BSA Conjugated Gastric Inhibitory Polypeptide (GIP)
Incretin hormone; Glucose Dependent Insulinotropic Peptide
- 編號(hào)CPA882Hu11
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 來源蛋白偶聯(lián)
- 原分子量1402.6Da
- 緩沖液成份磷酸鹽緩沖液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)-
-
應(yīng)用
Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 840 ¥ 2100 ¥ 4200 ¥ 12600 ¥ 31500
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
化學(xué)式
用法
PBS或其它。
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月,-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA882Hu01 | 胃泌素抑制肽(GIP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
CPA882Hu11 | 胃泌素抑制肽(GIP)牛血清白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
CPA882Hu21 | 胃泌素抑制肽(GIP)卵白蛋白偶聯(lián)物 | Immunogen; SDS-PAGE; WB. |
PAA882Hu08 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
PAA882Hu01 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
MAA882Hu21 | 胃泌素抑制肽(GIP)單克隆抗體 | WB,IHC. |
MAA882Hu22 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
MAA882Hu23 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
CEA882Hu | 胃泌素抑制肽(GIP)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA882Hu | 胃泌素抑制肽(GIP)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA882Hu11 | 胃泌素抑制肽(GIP)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Scientific Reports | The?anti-hyperglycemic?efficacy?of a?lipid-lowering?drug?Daming?capsule?and the?underlyingsignaling?mechanisms?in a?rat?model?of?diabetes?mellitus. [pubmed:27721485] |
Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats. [pubmed:28840471] |
Obesity?Surgery? | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague?… [Pubmed:29098544] |
BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity [] |
Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients [Pubmed: 31734225] |
OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats [Pubmed: 31701411] |
FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes [Pubmed:35251693] |
留言咨詢